Diclofenac Extended-Release Tablets bulk supplier for pharma manufacturers

Diclofenac Extended-Release Tablets Suppliers & Bulk Manufacturers

Available Forms: Extended-Release Tablets

Available Strengths: 100 mg

Reference Brands: Voltaren(US & EU)

Category: Arthritis

Diclofenac Extended-Release Tablets is available in Extended-Release Tablets and strengths such as 100 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Diclofenac Extended-Release Tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Diclofenac Extended-Release Tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Product Description: Diclofenac ER (Extended-Release) tablets are approved in the EU and US for managing chronic pain and inflammation. In the EU, brands like Voltaren ER are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval is based on comprehensive clinical data and biosimilarity assessments, with generic versions available. Both regions require detailed dossiers for approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We help facilitate efficient market access for diclofenac ER tablets, ensuring adherence to European and American standards for safe, effective long-term anti-inflammatory therapy.

Frequently Asked Questions

Yes, Diclofenac Extended-Release Tablets is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Diclofenac Extended-Release Tablets is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Pegloticase Injecatble

Strength:
8 mg/1.2 mL vial

Form: Injectable (IV solution)

Reference Brands: Krystexxa (US)

View Details
Colchicine Tablest

Strength:
0.6 mg

Form: Tablet

Reference Brands: Colcrys(US)

View Details
Febuxostat Tablets

Strength:
40 mg, 80 mg

Form: Oral Tablets

Reference Brands: Uloric(EU & US)

View Details
Allopurinol Tablets

Strength:
100 mg, 300 mg

Form: Oral Tablets

Reference Brands: Aloprim(US & EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.